In addition, optimal efficacy has been observed when Notch pathway inhibitors are combined with HER2 inhibitors in HER2-positive breast cancer [152, 153], with endocrine therapy in ER-positive breast cancer [154], and with taxanes and MET inhibitors in triple-negative breast cancer [155, 156]. The gene discussed is MET; the disease is triple-negative breast carcinoma.